Objective. Estimate the contribution of monocytes/macrophages to the disease process in rheumatoid arthritis (RA), by measuring the serum levels of the leucocyte-derived granular proteins: lysozyme, myeloperoxidase (MPO), lactoferrin and human neutrophil lipocalin (HNL).
Rheumatoid arthritis (RA) is a chronic inflammatory 10] and synovial [10, 11] levels of lysozyme in patients disease, affecting the joints and extra-articular tissues.
with RA. Similar content of lysozyme was found in In the synovium of the rheumatoid joint mononuclear peripheral blood neutrophils from patients with RA and cells, such as macrophages, lymphocytes and plasma healthy controls [12] . A higher content of lysozyme in cells, are the most numerous cells. Macrophages secrete granulocytes compared with monocytes and vice versa many substances either constitutively or after stimulahas been reported [13, 14] . In previous studies on RA tion [1] . Amongst these substances are different proteothe neutrophils were considered to be the dominating lytic enzymes, lysozyme and reactive oxygen contributors to the amount of lysozyme in serum. Later intermediates, important for cartilage and bone destrucinvestigations have indicated that monocytes and macrotion in RA [2, 3] .
phages are the dominating contributors to the lysozyme Monocytes and neutrophils contain intracellular content in serum [15, 16 ] . granular proteins, which are important for the host Myeloperoxidase (MPO) is a basic protein stored in defence. Lysozyme is an enzyme that hydrolyses glycosthe primary granules of neutrophils and in blood monoidic bonds and is thus able to hydrolyse the cell wall cytes, but not in tissue macrophages [17] . Lactoferrin is peptidoglycans of some micro-organisms and thereby a slightly basic, iron-binding protein, stored in the kill the organism [4] . It is found in monocytes and secondary granules of neutrophils [18] . It is also promacrophages [5] [6] [7] [8] , neutrophils [8] and glandular cells duced by exocrine glands such as the mammary glands, [5] . Previous investigations using an enzymatic method pancreas and salivary glands. Human neutrophil lipocato measure lysozyme have reported elevated serum [9, lin (HNL), also called human neutrophil N-formyl peptide-binding 24 kDa protein, 25 kDa a 2 -microglobulin-related protein and neutrophil gelatinase-associated Glucocorticoids have been used in the treatment of Controls RA for five decades [21] as effective anti-inflammatory Twenty-one healthy female and six healthy male indiagents with possible disease-modifying activity [22] . viduals served as controls. Their mean age was 48 yr Glucocorticoids exert at least part of their action at the (range 26-65 yr). None of the controls had any sympmolecular level by binding to specific receptors in the toms of infection or any inflammatory disease. The cytoplasm and then migrating to the nucleus, where patients and controls were informed according to the they bind to selective regulatory sites on DNA. This can Declaration of Helsinki and the study was accepted by result in increased or decreased expression of genes the local ethics committee. important for the inflammatory process [23] .
The aim of the present study was to re-evaluate serum Assays lysozyme as a measure of monocyte/macrophage activity The serum concentrations of lysozyme and HNL were in RA, using an immunological method, and to monitor measured by a double-antibody radioimmunoassay the effect of exogenous and endogenous glucocorticoids described in detail elsewhere [26 ] . Briefly, 50 ml of either on the secretory activity of macrophages.
sample or standard was mixed with 50 ml of specific anti-lysozyme/anti-HNL antibodies, diluted in assay buffer, and incubated for 3 h at room temperature.
Patients and methods
Thereafter, 2 ml of decanting suspension containing Sepharose anti-rabbit IgG was added and the incubation Patients continued for 30 min at room temperature. LysozymeTwenty-three patients with definite RA (17 women, six or HNL-antibody complexes bound on Sepharose men, mean age 61 yr, range 29-86 yr) according to the anti-rabbit IgG were separated and pelleted by means ARA criteria [24] were included in the study. The mean of centrifugation for 10 min at 4000 r.p.m. After duration of disease was 63 months (range 1 month to decantation the radioactivity was measured in a 43 yr). Another six patients with seronegative polygamma counter. arthritis not fulfilling the criteria for definite RA were
The serum concentration of MPO was assayed also studied. None of the patients had received glucocorby means of a double-antibody radioimmunoassay ticoid treatment for the past 3 months prior to inclusion (Pharmacia and Upjohn, Diagnostics AB, Uppsala, into the study and none of the patients had been treated Sweden). with second-line drugs. Most of the patients were treated
The serum concentration of lactoferrin was measured with non-steroidal anti-inflammatory drugs (NSAIDs).
by means of radioimmunoassay as previously Ten of the patients with definite RA and three of the described [27] . patients with seronegative polyarthritis were treated with prednisolone at an initial dose of 5-15 mg/day which Statistics was reduced to 5-7.5 mg/day during the first 2 weeks
Values are given as medians and inter-quartile ranges of treatment. In the majority of these patients, secondor total range. Non-parametric tests, Mann-Whitney line drugs, chloroquine (n = 6), sulphasalazine (n = 2), U-test, Wilcoxon matched-pair test and the Spearman methothrexate (n = 1) and oral gold (n = 1) were introrank correlation coefficient were used to analyse the duced as well. Blood samples were collected before the data. A P-value of <0.05 was considered significant. start of treatment and after 4-6 weeks. Blood samples
The statistical calculations were carried out using the were drawn before 10.00 a.m.
software Statistica (StatSoft. Inc., Tulsa, OK, USA). Eight of the patients with definite RA and three of the patients with seronegative polyarthritis were treated as in-patients with metyrapone for 2 days. Metyrapone Results inhibits the activity of the enzyme 11-b-hydroxylase in Serum concentration of lysozyme, MPO, HNL and the adrenal cortex and thus decreases the synthesis of lactoferrin cortisol. On day 1, oral doses of metyrapone of 750 mg were given at 6.00 a.m., 12.00 a.m., 6.00 p.m. and 12.00
The disease activity of the patients with RA was defined by the joint index (median Thompson index 82, range p.m. The first dose of 750 mg on day 2 was given at 6.00 a.m. Blood samples were collected the day before 0-225) and various laboratory data; median ESR 32 mm/h (range 8-120 mm/h), median CRP 24 mg/l the start of the metyrapone treatment and on the second day of metyrapone treatment. All blood samples were (∏10-184 mg/l ), median white blood cell count 7.5 × 109/l (range 4.3 × 109/l-18.1 × 109/l ) and median drawn at 7.30 a.m. One of these patients was on treatment with sulphasalazine 500 mg × 1.
platelet count 341 × 109/l (range 179 × 109-896 × 109/l ). Figure 1 shows that the serum concentrations The patients were assessed according to the Thompson index [25] of joint inflammation and to the duration of of lysozyme and MPO were significantly elevated in the patients with RA compared with the control individuals early morning stiffness. The blood samples were analysed for the following variables: haemoglobin, erythrocyte (P < 0.00001; P = 0.001, respectively). In Table 1 , peripheral blood neutrophil count, monocyte count, serum sedimentation rate/h ( ESR), C-reactive protein (CRP), white blood cell, neutrophil, monocyte and platelet concentration of HNL and lactoferrin are presented.
No difference was observed between the concentration counts.
presented in Table 2B . The serum cortisol level at 7.30 a.m. on day 2 of metyrapone treatment was significantly lower compared with the day before the start of treatment at 7.30 a.m. (162 nmol/l compared with 438 nmol/l, P < 0.01). The serum levels of lysozyme and MPO ( Table 3) were not influenced by metapyrone treatment, nor were those of HNL and lactoferrin (data not shown).
Discussion
In the present study, elevated serum levels of lysozyme together with elevated serum levels of MPO were observed in patients with RA compared with controls. In contrast the concentrations of lactoferrin and HNL were similar in both groups. Based on the results of previous investigations indicating that lysozyme in serum predominantly originates from monocytes/macrophages and to a lesser degree from neutrophils [13, 15, 16 ] , that MPO originates from monocytes and neutrophils [17] , and that lactoferrin and HNL originate from neutrophils [18] [19] [20] , the elevated serum level of lysozyme and macrophages, although macrophages have a higher basal production of lysozyme [7] . Tumour necrosis The effect of prednisolone treatment on the serum factor-a (TNF-a) stimulates lysozyme production by concentration of the leucocyte granular proteins monocytes and macrophages [7] and the release of lysozyme and MPO by neutrophils [31] . Furthermore, The clinical and laboratory data of the RA patients before and after 4-6 weeks on treatment with low-dose elevated levels of TNF-a in serum have been measured in RA [32] . The increased secretion of lysozyme into prednisolone are presented in Table 2A . The serum concentration of lysozyme was significantly lower in the the peripheral blood could thus be mediated by TNF-a.
Ten of the patients with RA included in the study patients after the treatment compared with before ( Fig. 2 ; P = 0.001). The concentration of MPO in serum were treated with low-dose prednisolone for approximately 1 month. The decrease in the serum levels of was also decreased by the treatment ( Fig. 3 ; P < 0.05). In Figs 2 and 3 patients with RA (n = 10) and seroneglysozyme and MPO after treatment suggests a diminished secretory activity of the monocytes/macrophages. ative polyarthritis (n = 3) are presented. The serum concentrations of HNL and lactoferrin were not influThese results are in concordance with our previous results, where low-dose prednisolone treatment enced by the prednisolone treatment (data not shown).
decreased the expression of integrin, complement and The effect of metyrapone on the serum concentration of Fcc-receptors on peripheral blood monocytes in RA the leucocyte granular proteins [30] . Macrophages contribute to the cartilage and bone destruction in RA. The reported disease-modifying effect Eight patients with RA were treated with metyrapone. production.
Inhibition of endogenous cortisol by metyrapone did not influence the circulating levels of the various granumore sensitive to lowered serum cortisol concentrations compared with the secretory activity by monocytes/ lar proteins measured before and after treatment. One explanation could be the short duration of treatment.
macrophages. Most of the patients receiving low-dose prednisolone Another possible explanation is that the release of lysozyme and MPO is not affected by endogenous treatment were also treated with second-line drugs. The second-line drugs, i.e. chloroquine, methotrexate, sulphacortisol. Our previous report showed that metyrapone treatment increased the expression of complement recepsalazine and gold salts affect leucocyte function in different ways. Auronofin was reported to inhibit the tor 1 and CD49f on peripheral blood monocytes [30] . The monocyte expression of these receptors seems to be cytokine-induced release of lysozyme by leucocytes [34] . 
